{"url":"https://lda.senate.gov/api/v1/filings/0bb9d1a5-388c-4fc1-adbb-3ffe86112e7e/","filing_uuid":"0bb9d1a5-388c-4fc1-adbb-3ffe86112e7e","filing_type":"RR","filing_type_display":"Registration","filing_year":2024,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/0bb9d1a5-388c-4fc1-adbb-3ffe86112e7e/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Clay White","dt_posted":"2024-11-15T11:30:45-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2412 Gretter Pl","registrant_address_2":null,"registrant_different_address":null,"registrant_city":"Alexandria","registrant_state":"VA","registrant_zip":"22311","registrant":{"id":401108457,"url":"https://lda.senate.gov/api/v1/registrants/401108457/","house_registrant_id":56491,"name":"EAGLE POINT STRATEGIES LLC","description":null,"address_1":"2412 Gretter Pl","address_2":null,"address_3":null,"address_4":null,"city":"Alexandria","state":"VA","state_display":"Virginia","zip":"22311","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CLAY WHITE","contact_telephone":"+1 435-421-9910","dt_updated":"2026-07-08T12:55:30.158550-04:00"},"client":{"id":63036,"url":"https://lda.senate.gov/api/v1/clients/63036/","client_id":63036,"name":"OBJECT PHARMA","general_description":"Biopharma company","client_government_entity":null,"client_self_select":false,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2024-11-12"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to the development of neurotoxin treatment for PTSD and other mental health related disorders in regards to veterans.","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":146339,"prefix":null,"prefix_display":null,"first_name":"CLAY","nickname":null,"middle_name":null,"last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Leg Director - Congressman Chris Stewart; Leg Director, Leg Asst - Congressman Jason Chaffetz","new":true}],"government_entities":[]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Issues related to the development of neurotoxin treatment for PTSD and other mental health related disorders in regards to veterans.","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":146339,"prefix":null,"prefix_display":null,"first_name":"CLAY","nickname":null,"middle_name":null,"last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff, Leg Director - Congressman Chris Stewart; Leg Director, Leg Asst - Congressman Jason Chaffetz","new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}